[1]曹鸣菲,雷德财,董秋月,等.NSCLC患者外周血血小板相关参数与临床病理特征的关系[J].医学信息,2023,36(18):90-93.[doi:10.3969/j.issn.1006-1959.2023.18.016]
　CAO Ming-fei,LEI De-cai,DONG Qiu-yue,et al.The Relationship Between Peripheral Blood Platelet Related Parameters and Clinicopathological Features in NSCLC Patients[J].Journal of Medical Information,2023,36(18):90-93.[doi:10.3969/j.issn.1006-1959.2023.18.016]
点击复制

NSCLC患者外周血血小板相关参数与临床病理特征的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年18期
页码:
90-93
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
The Relationship Between Peripheral Blood Platelet Related Parameters and Clinicopathological Features in NSCLC Patients
文章编号:
1006-1959（2023）18-0090-04
作者:
曹鸣菲; 雷德财; 董秋月; 等
（1.简阳市空分医院检验科，四川 简阳 641400；2.乐山市市中区肿瘤医院检验科，四川 乐山 641400；3.四川省肿瘤医院检验科，四川 成都 610041）
Author(s):
CAO Ming-fei; LEI De-cai; DONG Qiu-yue; et al.
(1.Department of Clinical Laboratoty,Kongfen Hispital,Jianyang 641400,Sichuan,China;2.Department of Clinical Laboratoty,Leshan Cancer Hospital,Leshan 614000,Sichuan,China;3.Department of Clinical Laboratoty,Sichuan Cancer Hospital,Chengdu 610041,Sichuan,China)
关键词:
非小细胞肺癌; 中性粒细胞与淋巴细胞比值; 血小板与淋巴细胞比值; 淋巴细胞与单核细胞比值
Keywords:
Non-small cell lung cancer; Neutrophil-lymphocyte ratio; Platelet-lymphocyte ratio; Lymphocyte-monocyte ratio
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.18.016
文献标志码:
A
摘要:
目的 探索NSCLC患者外周血血小板相关参数与临床病理特征的相关性，以及血小板相关参数在NSCLC诊治中的应用价值。方法 选取四川省肿瘤医院2021年1月-10月收治的300例NSCLC患者设为肺癌组，另收集同期健康体检人群100例设为对照组，比较两组外周血血小板相关参数表达水平，分析NSCLC患者外周血血小板相关参数与其临床病理特征的关系，另通过ROC曲线分析外周血血小板相关参数在NSCLC中的诊断价值。结果 肺癌组中PLR、NLR、MPV、PCT高于对照组，LMR低于对照组（P＜0.05），而两组PDW比较，差异无统计学意义（P＞0.05）；PLT与肿瘤直径有关，MPV与肿瘤分期、远端转移有关，PLR与病理类型、肿瘤分期以及远端转移有关，LMR与性别有关（P＜0.05）；ROC曲线显示，MPV和LMR诊断NSCLC的曲线下面积高于血小板其他参数。结论 NSCLC患者外周血血小板相关参数表达异常，与其临床病理特征密切相关，在NSCLC的诊断中具有重要价值。
Abstract:
Objective To explore the correlation between peripheral blood platelet-related parameters and clinicopathological features in patients with NSCLC, and the application value of platelet-related parameters in the diagnosis and treatment of NSCLC.Methods A total of 300 NSCLC patients admitted to Sichuan Cancer Hospital from January to October 2021 were selected as the lung cancer group, and 100 healthy people in the same period were collected as the control group. The expression levels of platelet-related parameters in peripheral blood of the two groups were compared, and the relationship between platelet-related parameters in peripheral blood of NSCLC patients and their clinicopathological characteristics was analyzed. In addition, the diagnostic value of platelet-related parameters in peripheral blood in NSCLC was analyzed by ROC curve.Results The PLR, NLR, MPV and PCT in the lung cancer group were higher than those in the control group, and the LMR was lower than that in the control group (P<0.05), while there was no significant difference in PDW between the two groups (P>0.05). PLT was related to tumor diameter, MPV was related to tumor stage and distant metastasis, PLR was related to pathological type, tumor stage and distant metastasis, and LMR was related to gender (P<0.05). ROC curve analysis showed that the area under the curve of MPV and LMR in NSCLC was higher than that of other platelet parameters.Conclusion The abnormal expression of platelet-related parameters in peripheral blood of NSCLC patients is closely related to their clinicopathological features and has important value in the diagnosis of NSCLC.

参考文献/References:

[1]曹毛毛,陈万青.GLOBOCAN 2020全球癌症统计数据解读[J].中国医学前沿杂志(电子版),2021,13(3):63-69.[2]邢力刚,马晓林.2021版《中华医学会肿瘤学分会肺癌临床诊疗指南》非小细胞肺癌诊疗更新专家解读[J].疑难病杂志,2022,21(6):557-560.[3]尹蕾,杨旭东,杨悦,等.中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J].实用肿瘤学杂志,2021,35(2):117-124.[4]马云飞,于明薇,李光达,等.肺癌血小板和中性粒细胞计数与淋巴细胞计数比值的临床特点及预后价值研究[J].中华肿瘤防治杂志,2021,28(12):921-926.[5]谭钦全,江冠铭,刘克军,等.血小板/淋巴细胞比值对表皮生长因子受体突变型晚期非小细胞肺癌靶向治疗效果及预后影响的观察性研究[J].癌症进展,2020,18(7):690-693.[6]孙珊珊,冯虎,毕莎杉.非小细胞肺癌预后标志物和预测相关性microRNA的研究[J].中国实验诊断学,2022,26(5):728-734.[7]赵坤宇,亓妍文,秦国慧,等.中性粒细胞淋巴细胞比值和淋巴细胞单核细胞比值对PD-1抑制剂治疗的晚期非小细胞肺癌患者预后的预测价值[J].郑州大学学报(医学版),2022,57(3):379-382.[8]Garshick MS,Tawil M,Barrett TJ,et al.Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis Via COX-1 (Cyclooxygenase-2)[J].Arteriosclerosis Thrombosis and Vascular Biology,2020,40(5):1340-1351.[9]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[10]Best MG,Sol N,Kooi I,et al.RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer,Multiclass,and Molecular Pathway Cancer Diagnostics[J].Cancer Cell,2015,28(5):666-676.[11]McAllister SS,Weinberg RA.The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis[J].Nat Cell Biol,2014,16(8):717-727.[12]Best MG,Wesseling P,Wurdinger T.Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring[J].Cancer Res,2018,78(13):3407-3412.[13]Liu L,Lin F,Ma X,et al.Tumor-educated platelet as liquid biopsy in lung cancer patients[J].Crit Rev Oncol Hematol,2020,146:102863.[14]Junqueira-Neto S,Batista IA,Costa JL,et al.Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA[J].Acta Cytol,2019,63(6):479-488.[15]Kinoshita T,Goto T.Links between Inflammation and Post-operative Cancer Recurrence[J].J Clin Med,2022,10(2):228.[16]韦琼,姚坚,吕学东.进展期非小细胞肺癌血清miR125b、巨噬细胞抑制因子1表达变化与抗PD-1/PD-L1单抗治疗疗效的关系[J].广东药科大学学报,2022,38(2):119-125.[17]朱飞,魏宇峰,王增,等.吉西他滨相关血小板减少对晚期非小细胞肺癌患者生存时间的影响[J].中国药师,2018,21(3):429-431.[18]樊华,弥鹏,杨波,等.肺癌患者外周血血小板参数检测分析及临床意义[J].现代检验医学杂志,2019,34(6):97-100.[19]韩蕃颉,王海滨,苏新云,等.3项血清肿瘤标志物、SAA及DCLK1联合检测在非小细胞癌患者预后判断中的价值[J].国际检验医学杂志,2021,42(17):2154-2157.[20]沈凯凯,吕镗烽.非小细胞肺癌患者血小板增多与临床病理的关系分析[J].临床肿瘤学杂志,2019,24(4):324-328.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]陈学敏,彭 琼.中性粒细胞与淋巴细胞比值联合癌胚抗原对结直肠癌早期诊断的研究[J].医学信息,2019,32(02):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
　CHEN Xue-min,PENG Qiong.Early Diagnosis of Colorectal Cancer by Neutrophil-lymphocyte Ratio Combined with Carcinoembryonic Antigen[J].Journal of Medical Information,2019,32(18):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(18):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(18):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(18):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(18):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[9]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[10]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(18):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[11]张冠卿,龙 勇,余海彬,等.治疗前NLR对ICIs治疗非小细胞肺癌患者的预后预测价值的Meta分析[J].医学信息,2024,37(07):30.[doi:10.3969/j.issn.1006-1959.2024.07.005]
　ZHANG Guan-qing,LONG Yong,YU Hai-bin,et al.Meta-analysis of the Prognostic Value of Pre-treatment NLR in Patients with Non-small Cell Lung Cancer Treated with ICIs[J].Journal of Medical Information,2024,37(18):30.[doi:10.3969/j.issn.1006-1959.2024.07.005]

更新日期/Last Update: 1900-01-01